How ‘diabesity drugs’ could change the investment landscape
Trial results from Eli Lilly add to a growing body of evidence that suggests GLP-1 drugs, which include treatments like Lilly’s Mounjaro and Novo Nordisk’s Wegovy, have medical benefits beyond diabetes and weight loss.
Tematica CIO Chris Versace explains how these so-called ‘diabesity drugs‘ could affect healthcare and why their impact, positive and negative, could not be known for some time. He also discusses the impact of oil prices on monetary policy and Netflix.
(AI Video Summary)
Fed's comments on inflation
In this IGTV interview, Angeline Ong and guest Chris Versace, Tematica's CIO, discuss how Fed comments, especially from Jerome Powell on inflation, reflect widely recognised concerns about inflationary pressures not abating. They emphasise the importance of interpreting data objectively to inform investments. The discussion also touches on oil's potential impact on inflation, with prices possibly swayed by geopolitical events and economic performance.
Netflix and Eli Lilly
The conversation covers the anticipation around Netflix’s earnings and the strategic focuses that could influence its stock value. Additionally, they explore Eli Lilly's advancements in weight loss drugs potentially aiding sleep apnea and address the growing interest in the obesity treatment market, highlighting the significance of drug side effects and delivery methods.
This information has been prepared by IG, a trading name of IG Markets Ltd and IG Markets South Africa Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.
Seize a share opportunity today
Go long or short on thousands of international stocks.
- Increase your market exposure with leverage
- Get spreads from just 0.1% on major global shares
- Trade CFDs straight into order books with direct market access
Live prices on most popular markets
- Forex
- Shares
- Indices
Prices above are subject to our website terms and agreements. Prices are indicative only
